|Bid||144.00 x 1000|
|Ask||153.00 x 1200|
|Day's Range||144.97 - 149.18|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 1, 2019 - Oct 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||227.31|
GW Pharmaceuticals, NetApp, KB Home, PulteGroup, M/I Homes, Lennar and Toll Brothers highlighted as Zacks Bull and Bear of the Day
HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
From global marijuana legalization to the rapidly increasing use of CBD as a wellness product, all of this should help Tilray witness an uptick in second-quarter revenues.
Quarterly results, more quarterly results, a new buyout and a potentially new Nasdaq marijuana stock -- last week was far from boring in the cannabis industry.
- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST -.
GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $164.05, moving -1.12% from the previous trading session.